Payment overview · 2025
General Payments
$807.30
40 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Evan Burton, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1114213253
Verified facts
What the public records show
CMS Open Payments records show Robert Evan Burton, D.O. received $807.30 in general payments during 2025 across 40 reported records.
PFIZER INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Enbrel by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $163.91 | 20.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.62 | 15.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.38 | 10.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.80 | 10.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.53 | 6.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.50 | 6.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.44 | 5.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 4.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.12 | 4.6% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $28.24 | 3.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $22.80 | 2.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.18 | 2.2% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $18.11 | 2.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.39 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.85 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.73 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $769.60 | 38 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $103.83 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.00 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.51 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $60.27 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.53 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.50 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.56 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.62 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 202 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 47 |
| Omeprazole | Omeprazole | 143 | 37 |
| Gabapentin | Gabapentin | 138 | 28 |
| Lisinopril | Lisinopril | 125 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 25 |
| Ozempic | Semaglutide | 95 | 19 |
| Metformin Hcl Er | Metformin Hcl | 91 | 20 |
| Irbesartan | Irbesartan | 79 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 26 |
| Meloxicam | Meloxicam | 74 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 19 |
| Losartan Potassium | Losartan Potassium | 73 | 17 |
| Linzess | Linaclotide | 72 | 12 |
| Prednisone | Prednisone | 72 | 33 |
| Montelukast Sodium | Montelukast Sodium | 71 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 19 |
| Alprazolam | Alprazolam | 62 | 18 |
| Simvastatin | Simvastatin | 60 | 15 |
| Furosemide | Furosemide | 59 | 16 |
| Trazodone Hcl | Trazodone Hcl | 58 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 12 |
| Ondansetron Odt | Ondansetron | 54 | 15 |
| Potassium Chloride | Potassium Chloride | 54 | 12 |
| Farxiga | Dapagliflozin Propanediol | 52 | 12 |
| Bupropion Xl | Bupropion Hcl | 51 | 14 |
| Carvedilol | Carvedilol | 50 | 15 |
| Metformin Hcl | Metformin Hcl | 49 | 12 |
| Eliquis | Apixaban | 48 | 11 |
| Jardiance | Empagliflozin | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Sucralfate | Sucralfate | 40 | 17 |
| Famotidine | Famotidine | 38 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 32 |
| Azelastine Hcl | Azelastine Hcl | 35 | 14 |
| Celecoxib | Celecoxib | 35 | 12 |
| Cefdinir | Cefdinir | 34 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Levofloxacin | Levofloxacin | 26 | 20 |
| Nystatin | Nystatin | 26 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 12 |
| Allopurinol | Allopurinol | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 18 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 11 |
| Mupirocin | Mupirocin | 18 | 15 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 16 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tenormin | Atenolol | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $807.30 · 40 records | PFIZER INC. | ABRYSVO, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, Flector, JARDIANCE, LEQVIO, Licart, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REZDIFFRA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tirosint, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error